Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: Importance of liposomal delivery and CpG motifs

Antiviral Research

Volumn 81, Issue 1, 2009, Pages 37-46

  Gowen, Brian B ^a   Fairman, Jeff ^b   Dow, Steven ^c   Troyer, Ryan ^c   Wong, Min Hui ^a   Jung, Kie Hoon ^a   Melby, Peter C ^d   Morrey, John D ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b Juvaris BioTherapeutics   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiviral; CpG; Liposomes; Phlebovirus; Punta Toro virus; Rift Valley fever

Indexed keywords

ANTIVIRUS AGENT; CATIONIC LIPOSOME DNA COMPLEX; CPG OLIGODEOXYNUCLEOTIDE; NUCLEIC ACID; PLASMID DNA; POLYINOSINIC POLYCYTIDYLIC ACID; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HAMSTER; IMMUNOTHERAPY; INFECTION PREVENTION; LIPOSOMAL DELIVERY; LIVER INJURY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHLEBOVIRAL INFECTION; PRIORITY JOURNAL; SURVIVAL; TH1 CELL; TISSUE INJURY; VIRUS INFECTION; VIRUS LOAD;

ANIMALS; CRICETINAE; CYTOKINES; DNA; FEMALE; HUMANS; LIPOSOMES; LIVER; MESOCRICETUS; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PHLEBOTOMUS FEVER; PHLEBOVIRUS; PLASMIDS;

ANIMALIA; BUNYAVIRIDAE; CRICETINAE; PHLEBOVIRUS; PUNTA TORO VIRUS;

EID: 57149086632     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.09.001     Document Type: Article

References (43)

1. Akira S., and Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4 (2004) 499-511
2. Amacher D.E. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul. Toxicol. Pharmacol. 27 (1998) 119-130
3. Anderson Jr. G.W., Slayter M.V., Hall W., and Peters C.J. Pathogenesis of a phleboviral infection (Punta Toro virus) in golden Syrian hamsters. Arch. Virol. 114 (1990) 203-212
4. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S., Wagner H., and Lipford G.B. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9237-9242
5. Bray M. Pathogenesis of viral hemorrhagic fever. Curr. Opin. Immunol. 17 (2005) 399-403
6. Brown E.J., and Frazier W.A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11 (2001) 130-135
7. Dallas P.B., Gottardo N.G., Firth M.J., Beesley A.H., Hoffmann K., Terry P.A., Freitas J.R., Boag J.M., Cummings A.J., and Kees U.R. Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR - how well do they correlate?. BMC Genomics 6 (2005) 59
8. Dow S.W., Fradkin L.G., Liggitt D.H., Willson A.P., Heath T.D., and Potter T.A. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163 (1999) 1552-1561
9. Fisher A.F., Tesh R.B., Tonry J., Guzman H., Liu D., and Xiao S.Y. Induction of severe disease in hamsters by two sandfly fever group viruses, Punta toro and Gabek Forest (Phlebovirus, Bunyaviridae), similar to that caused by Rift Valley fever virus. Am. J. Trop. Med. Hyg. 69 (2003) 269-276
10. Flick R., and Bouloy M. Rift Valley fever virus. Curr. Mol. Med. 5 (2005) 827-834
11. Geisbert T.W., and Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10 (2004) S110-S121
12. Gerdes G.H. Rift valley fever. Vet. Clin. North Am. Food Anim. Pract. 18 (2002) 549-555
13. Goodbourn S., Didcock L., and Randall R.E. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81 (2000) 2341-2364
14. Gowen B.B., Fairman J., Smee D.F., Wong M.H., Jung K.H., Pace A.M., Heiner M.L., Bailey K.W., Dow S.W., and Sidwell R.W. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res. 69 (2006) 165-172
15. Gowen B.B., and Holbrook M.R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res. 78 (2008) 79-90
16. Gowen B.B., Hoopes J.D., Wong M.H., Jung K.H., Isakson K.C., Alexopoulou L., Flavell R.A., and Sidwell R.W. TLR3 deletion limits mortality and disease severity due to Phlebovirus infection. J. Immunol. 177 (2006) 6301-6307
17. Gowen B.B., Judge J.W., Wong M.H., Jung K.H., Aylsworth C.F., Melby P.C., Rosenberg B., and Morrey J.D. Immunoprophylaxis of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with recombinant Eimeria profilin-like antigen. Int. Immunopharmacol. 8 (2008) 1089-1094
18. Gowen B.B., Smee D.F., Wong M.H., Judge J.W., Jung K.H., Bailey K.W., Pace A.M., Rosenberg B., and Sidwell R.W. Recombinant Eimeria protozoan protein elicits resistance to acute phlebovirus infection in mice but not hamsters. Antimicrob. Agents Chemother. 50 (2006) 2023-2029
19. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mendenhall M., Bailey K.W., Furuta Y., and Sidwell R.W. In vitro and in vivo activities of T-705 against Arenavirus and Bunyavirus infections. Antimicrob. Agents Chemother. 51 (2007) 3168-3176
20. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mitchell W.M., Alexopoulou L., Flavell R.A., and Sidwell R.W. TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J. Immunol. 178 (2007) 5200-5208
21. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
22. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., and Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434 (2005) 772-777
23. Ishii K.J., Coban C., Kato H., Takahashi K., Torii Y., Takeshita F., Ludwig H., Sutter G., Suzuki K., Hemmi H., Sato S., Yamamoto M., Uematsu S., Kawai T., Takeuchi O., and Akira S. A toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 7 (2006) 40-48
24. Karaghiosoff M., Steinborn R., Kovarik P., Kriegshauser G., Baccarini M., Donabauer B., Reichart U., Kolbe T., Bogdan C., Leanderson T., Levy D., Decker T., and Muller M. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 4 (2003) 471-477
25. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
26. Latour S., Tanaka H., Demeure C., Mateo V., Rubio M., Brown E.J., Maliszewski C., Lindberg F.P., Oldenborg A., Ullrich A., Delespesse G., and Sarfati M. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J. Immunol. 167 (2001) 2547-2554
27. Morrill J.C., Jennings G.B., Cosgriff T.M., Gibbs P.H., and Peters C.J. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Rev. Infect. Dis. 11 Suppl. 4 (1989) S815-S825
28. Morrill J.C., Jennings G.B., Johnson A.J., Cosgriff T.M., Gibbs P.H., and Peters C.J. Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch. Virol. 110 (1990) 195-212
29. NIAID, 2002. The Counter-Bioterrorism Research Agenda of the National Institute of Allergy and Infectious Diseases (NIAID) for CDC Category A Agents.
30. Peters C.J., and LeDuc J.W. Bunyaviruses, phleboviruses, and related viruses. In: Belshe R.B. (Ed). Textbook of Human Virology (1984), PSG Publishing Co., Littleton 547-598
31. Peters C.J., and Meegan J.M. Rift Valley fever. In: Beran G.W. (Ed). Handbook Series of Zooneses (1981), CRC Press, Boca Raton 403-420
32. Pifat D.Y., and Smith J.F. Punta Toro virus infection of C57BL/6J mice: a model for phlebovirus-induced disease. Microb. Pathog. 3 (1987) 409-422
33. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27 (1938) 493-497
34. Sidwell R.W., Huffman J.H., Barnard D.L., Smee D.F., Warren R.P., Chirigos M.A., Kende M., and Huggins J. Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. Antiviral Res. 25 (1994) 105-122
35. Sidwell R.W., Huffman J.H., Barnett B.B., and Pifat D.Y. In vitro and in vivo Phlebovirus inhibition by ribavirin. Antimicrob. Agents Chemother. 32 (1988) 331-336
36. Sidwell R.W., Huffman J.H., Smee D.F., Gilbert J., Gessaman A., Pease A., Warren R.P., Huggins J., and Kende M. Potential role of immunomodulators for treatment of phlebovirus infections of animals. Ann. N. Y. Acad. Sci. 653 (1992) 344-355
37. Stetson D.B., and Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 24 (2006) 93-103
38. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., Ohba Y., and Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448 (2007) 501-505
39. Yasuda K., Ogawa Y., Kishimoto M., Takagi T., Hashida M., and Takakura Y. Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochem. Biophys. Res. Commun. 293 (2002) 344-348
40. Yasuda K., Ogawa Y., Yamane I., Nishikawa M., and Takakura Y. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J. Leukoc. Biol. 77 (2005) 71-79
41. Yasuda K., Yu P., Kirschning C.J., Schlatter B., Schmitz F., Heit A., Bauer S., Hochrein H., and Wagner H. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J. Immunol. 174 (2005) 6129-6136
42. Yuen T., Wurmbach E., Pfeffer R.L., Ebersole B.J., and Sealfon S.C. Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res. 30 (2002) e48
43. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., Bosio C., and Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176 (2006) 7335-7345